226 related articles for article (PubMed ID: 34591965)
1. Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations.
Mair MJ; Berger JM; Berghoff AS; Starzer AM; Ortmayr G; Puhr HC; Steindl A; Perkmann T; Haslacher H; Strassl R; Tobudic S; Lamm WW; Raderer M; Mitterer M; Fuereder T; Fong D; Preusser M
JAMA Oncol; 2022 Jan; 8(1):106-113. PubMed ID: 34591965
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
3. Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.
Yazaki S; Yoshida T; Kojima Y; Yagishita S; Nakahama H; Okinaka K; Matsushita H; Shiotsuka M; Kobayashi O; Iwata S; Narita Y; Ohba A; Takahashi M; Iwasa S; Kobayashi K; Ohe Y; Yoshida T; Hamada A; Doi T; Yamamoto N
JAMA Oncol; 2021 Aug; 7(8):1141-1148. PubMed ID: 34047762
[TBL] [Abstract][Full Text] [Related]
4. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
Stellini R; Gianello R; Gomarasca W
Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
[TBL] [Abstract][Full Text] [Related]
5. Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers.
Jantarabenjakul W; Chantasrisawad N; Puthanakit T; Wacharapluesadee S; Hirankarn N; Ruenjaiman V; Paitoonpong L; Suwanpimolkul G; Torvorapanit P; Pradit R; Sophonphan J; Putcharoen O
Asian Pac J Allergy Immunol; 2022 Sep; 40(3):269-277. PubMed ID: 34717527
[TBL] [Abstract][Full Text] [Related]
6. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
Özgür D; Tütüncü EE
Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
[TBL] [Abstract][Full Text] [Related]
7. Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers.
Demirbakan H; Koçer I; Erdoğan M; Bayram A
Public Health; 2022 Apr; 205():1-5. PubMed ID: 35219127
[TBL] [Abstract][Full Text] [Related]
8. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.
Giuliano AR; Lancet JE; Pilon-Thomas S; Dong N; Jain AG; Tan E; Ball S; Tworoger SS; Siegel EM; Whiting J; Mo Q; Cubitt CL; Dukes CW; Hensel JA; Keenan RJ; Hwu P
JAMA Oncol; 2022 May; 8(5):748-754. PubMed ID: 35266953
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents.
Fenioux C; Teixeira L; Fourati S; Melica G; Lelievre JD; Gallien S; Zalcman G; Pawlotsky JM; Tournigand C
JAMA Oncol; 2022 Apr; 8(4):612-617. PubMed ID: 34994776
[TBL] [Abstract][Full Text] [Related]
11. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response.
Ontañón J; Blas J; de Cabo C; Santos C; Ruiz-Escribano E; García A; Marín L; Sáez L; Beato JL; Rada R; Navarro L; Sainz de Baranda C; Solera J
EBioMedicine; 2021 Nov; 73():103656. PubMed ID: 34740112
[TBL] [Abstract][Full Text] [Related]
12. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
13. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers.
Bayram A; Demirbakan H; Günel Karadeniz P; Erdoğan M; Koçer I
J Med Virol; 2021 Sep; 93(9):5560-5567. PubMed ID: 34019704
[TBL] [Abstract][Full Text] [Related]
15. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
Tortorella C; Aiello A; Gasperini C; Agrati C; Castilletti C; Ruggieri S; Meschi S; Matusali G; Colavita F; Farroni C; Cuzzi G; Cimini E; Tartaglia E; Vanini V; Prosperini L; Haggiag S; Galgani S; Quartuccio ME; Salmi A; Repele F; Altera AMG; Cristofanelli F; D'Abramo A; Bevilacqua N; Corpolongo A; Puro V; Vaia F; Capobianchi MR; Ippolito G; Nicastri E; Goletti D;
Neurology; 2022 Feb; 98(5):e541-e554. PubMed ID: 34810244
[TBL] [Abstract][Full Text] [Related]
16. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study.
Ward V; Wei J; Gordon W; Barnes E; Dunachie S; Jeffery K; Eyre D; O'Donnell AM
BMJ Open; 2022 Dec; 12(12):e066766. PubMed ID: 36456004
[TBL] [Abstract][Full Text] [Related]
18. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.
Oosting SF; van der Veldt AAM; GeurtsvanKessel CH; Fehrmann RSN; van Binnendijk RS; Dingemans AC; Smit EF; Hiltermann TJN; den Hartog G; Jalving M; Westphal TT; Bhattacharya A; van der Heiden M; Rimmelzwaan GF; Kvistborg P; Blank CU; Koopmans MPG; Huckriede ALW; van Els CACM; Rots NY; van Baarle D; Haanen JBAG; de Vries EGE
Lancet Oncol; 2021 Dec; 22(12):1681-1691. PubMed ID: 34767759
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine.
Lombardi A; Renisi G; Consonni D; Oggioni M; Bono P; Uceda Renteria S; Piatti A; Pesatori AC; Castaldi S; Muscatello A; Riboldi L; Ceriotti F; Gori A; Bandera A
BMC Infect Dis; 2022 Jan; 22(1):97. PubMed ID: 35090388
[TBL] [Abstract][Full Text] [Related]
20. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K
Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
